Everything below concerns glucose-dependent. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
== See also == Gladys Boyd, paediatrician, pioneer in the treatment of juvenile diabetes. Charles Best, co-discoverer of insulin. Elizabeth Hughes Gossett, a notable early recipient of insulin. Frederick Banting, co-discoverer of insulin. Islets of Langerhans Pancreas James D. Havens, first American to receive insulin from Toronto.
== Applications == As a positron emitter, 64Cu has been used to produce experimental and clinical radiopharmaceuticals for the imaging of a range of conditions. Its beta emissions also raise the possibility of therapeutic applications. Compared to typical PET radionuclides it has a relatively long half-life, which can be advantageous for therapy, and for imaging certain physiological processes.
A wide gap exists between developed and developing countries' 3G and 4G cellular coverage, and issues such as dropped calls, delays, and weak signals hamper telecommunications efficacy in rural areas. Even when countries overcome infrastructural challenges, the price of network connectivity can exclude smallholders, poor farmers, and those in remote areas. Similar accessibility and affordability issues exist for digital devices and digital accounts. According to a 2016 GSMA report, of the 750 million-plus farmers in the 69 surveyed countries, about 295 million had a mobile phone; only 13 million had both a mobile phone and a mobile money account. Despite lingering gaps in network coverage, ICT access has skyrocketed in recent years. In 2007, only 1% of people in developing countries used Internet, but by 2015, 40% did. Mobile-broadband subscriptions, which increased thirty-fold between 2005 and 2015, drove much of this growth. As a key enabler of agricultural change, digital infrastructure requires further development, but growing ICT access indicates progress.
== History == 2C-B, the first major 2C drug and an analogue of mescaline, was first described by Alexander Shulgin in the 1970s. Richard Glennon and colleagues synthesized and described 25B-NB (N-benzyl-2C-B) along with a variety of other 25-NB derivatives in 1994. It was observed at the time that 25B-NB had slightly higher affinity for the serotonin 5-HT2A receptor than 2C-B and that other 25-NB derivatives with substituents on the benzyl ring showed very high affinity for the receptor, though functional data were not reported. N-Benzyl derivatives of the ketanserin-related quinazolinedione EZS-8, such as RH-34, were first described by Heinz Pertz, Sigurd Elz, and Ralf Heim by 1996 or 1998. NBOMe-mescaline and NBOMe-escaline were first described by Pertz and colleagues by 1999, while 25B-NBOMe was first described by Heim and colleagues in 1999. 25I-NBOMe and other 25-NB compounds such as 25TFM-NBOMe and 2CBFly-NBOMe were described by Heim and colleagues by 2000. 25I-NBOMe and other 25-NB drugs were subsequently further described by Heim in his dissertation in 2003. 25C-NBOMe was not described in the literature until 2010. The discovery of the 25-NB compounds by Heim and colleagues has been described by David E. Nichols as structurally remarkable, since N-alkylation of psychedelic phenethylamines, for instance Beatrice (N-methyl-DOM), has otherwise invariably abolished the hallucinogenic effects of this class of compounds.
Sources: en.wikipedia.org
==== New Zealand ==== In February 2022, Pharmac recommended, with medium priority, funding for people aged 12 years and over. In December 2022, Pharmac announced it had reached a provisional agreement with Vertex funding Trikafta starting on 1 April 2023 for patients aged six or above.
The Keewatin Region was a district of the Northwest Territories, in use as an administrative and statistical division until the creation of Nunavut in 1999. The majority of Keewatin Region fell on the Nunavut side of the boundary and was reconstituted as Kivalliq Region within the new territory, while a strip on the region's west side remaining in the NWT was transferred to Fort Smith Region. Kivalliq continues to be referred to as "Keewatin Region, Nunavut" in some circumstances, such as by Statistics Canada. The regional seat of the Keewatin Region was Rankin Inlet.
== History == Historically, potassium alum was used extensively in the wool industry from Classical antiquity, during the Middle Ages, and well into 19th century as a mordant or dye fixative in the process of turning wool into dyed bolts of cloth.
Sources: en.wikipedia.org
==== Pregnancy and breastfeeding ==== The metabolism of caffeine is reduced in pregnancy, especially in the third trimester, and the half-life of caffeine during pregnancy can be increased up to 15 hours (as compared to 2.5 to 4.5 hours in non-pregnant adults). Evidence regarding the effects of caffeine on pregnancy and for breastfeeding are inconclusive. There is limited primary and secondary advice for, or against, caffeine use during pregnancy and its effects on the fetus or newborn. The UK Food Standards Agency has recommended that pregnant women should limit their caffeine intake, out of prudence, to less than 200 mg of caffeine a day – the equivalent of two cups of instant coffee, or one and a half to two cups of fresh coffee. The American Congress of Obstetricians and Gynecologists (ACOG) concluded in 2010 that caffeine consumption is safe up to 200 mg per day in pregnant women. For women who breastfeed, are pregnant, or may become pregnant, Health Canada recommends a maximum daily caffeine intake of no more than 300 mg, or a little over two 8 oz (237 mL) cups of coffee. A 2017 systematic review on caffeine toxicology found evidence supporting that caffeine consumption up to 300 mg/day for pregnant women is generally not associated with adverse reproductive or developmental effect. There are conflicting reports in the scientific literature about caffeine use during pregnancy.
Samoyeds can compete in dog agility trials, carting, obedience, showmanship, flyball, tracking, mushing and herding events. Herding instincts and trainability can be measured at non-competitive herding tests. Samoyeds exhibiting basic herding instincts can be trained to compete in herding trials.
Alginate biopolymer applications range from packaging, textile and food industry to biomedical and chemical engineering. The first ever application of alginate was in the form of wound dressing, where its gel-like and absorbent properties were discovered. When applied to wounds, alginate produces a protective gel layer that is optimal for healing and tissue regeneration, and keeps a stable temperature environment. Additionally, there have been developments with alginate as a drug delivery medium, as drug release rate can easily be manipulated due to a variety of alginate densities and fibrous composition.
== Adverse effects == Among those with keratoconus who worsen, CXL may be used. In this group, the most common side effects are haziness of the cornea, punctate keratitis, corneal striae, corneal epithelium defect, and eye pain. In those who use it after post-LASIK ectasia, the most common side effects are haziness of the cornea, corneal epithelium defect, corneal striae, dry eye, eye pain, punctate keratitis, and sensitivity to bright lights. There are no long-term studies about crosslinking effect on pregnancy and lactation. According to a manufacturer crosslinking should not be performed on pregnant women.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.